Detalhe da pesquisa
1.
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Ann Rheum Dis
; 2024 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569851
2.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
N Engl J Med
; 382(3): 211-221, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851795
3.
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
Int J Mol Sci
; 22(20)2021 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34681945
4.
Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 1945-1959, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691451
5.
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Clin Cancer Res
; 27(6): 1631-1640, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355200
6.
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
; 26(4): 846-854, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31676670
7.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Lancet Rheumatol
; 1(4): e208-e219, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229377
8.
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Clin Cancer Res
; 24(24): 6212-6222, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093454
9.
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Clin Cancer Res
; 24(16): 3857-3866, 2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29716923
10.
Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
Arthritis Rheumatol
; 70(12): 2087-2095, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29956883
11.
Autoimmune manifestations in aged mice arise from early-life immune dysregulation.
Sci Transl Med
; 8(361): 361ra137, 2016 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27798262
12.
Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies.
Arthritis Rheumatol
; 66(4): 1022-33, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24757153
13.
The plasma cell signature in autoimmune disease.
Arthritis Rheumatol
; 66(1): 173-84, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24431284
14.
Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.
J Clin Invest
; 124(12): 5337-51, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25384217
15.
Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study.
PLoS One
; 8(8): e58557, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23990866